Anika Therapeutics, a global leader in osteoarthritis pain management and regenerative solutions, announced a significant leadership transition in a recent filing.
Stephen Griffin, the current CFO and COO, has been appointed as the new President and CEO, effective February 1, 2026.
Cheryl Blanchard, the outgoing CEO, will assume the role of Executive Chair of the Board of Directors.
New CEO Appointment
Stephen Griffin, with a background in finance and operations, to lead Anika towards profitable growth and innovation.
Executive Chair Transition
Cheryl Blanchard, after six years as CEO, will continue to support the company's transition as Executive Chair.
Board Restructuring
The resignation of Susan N. Vogt will lead to a shift in the composition of the Board of Directors.
- The appointment of Stephen Griffin marks a strategic move towards operational excellence and growth for Anika Therapeutics.
- Cheryl Blanchard's continued involvement as Executive Chair ensures a smooth leadership transition for the company.
The leadership changes at Anika Therapeutics signify a new chapter focused on growth and innovation in the osteoarthritis sector.